Combined surgery enables better graft fixation

Article

A stable IOL, decreased pseudophacodonesis and improved graft fixation are the benefits of combining Descemet membrane endothelial keratoplasty with glued intrascleral haptic fixation of a posterior-chamber IOL in patients with aphakic or pseudophakic bullous keratopathy, according to recently published research.

A stable IOL, decreased pseudophacodonesis and improved graft fixation are the benefits of combining Descemet membrane endothelial keratoplasty with glued intrascleral haptic fixation of a posterior-chamber IOL in patients with aphakic or pseudophakic bullous keratopathy, according to recently published research.

The researchers base their conclusions on a study of 6 patients who had corneal decompensation and inadequate capsular support requiring implantation/exchange of an IOL; all underwent the single-staged procedure at a tertiary care centre. The investigators injected air during surgery to judge the stability of the anterior chamber and structure of the iris diaphragm–IOL complex. They performed iridoplasties in two of the patients. They observed patients after surgery.

Regarding other complications, 1 patient had a partial graft detachment that had to be re-bubbled, and 1 patient had a small peripheral detachment that spontaneously resolved. The graft remained attached in all patients.

Visual acuity (VA) improved in all patients and corrected distance VA significantly changed following surgery. Mean preoperative corrected distance VA was 0.11 ± 0.07, and mean postoperative corrected distance VA was 0.7 ± 0.17.

The mean postoperative endothelial cell density at 6 months was 1710.3 ± 205.8 cells/mm2.

To read the abstract of the study, go to the Journal of Refractive Surgery.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.